Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products
Abstract Background Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigati...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Stem Cell Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13287-021-02147-6 |
id |
doaj-025f7192fd16410c9a892234036dc7cb |
---|---|
record_format |
Article |
spelling |
doaj-025f7192fd16410c9a892234036dc7cb2021-01-31T12:16:04ZengBMCStem Cell Research & Therapy1757-65122021-01-011211710.1186/s13287-021-02147-6Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy productsAnjali Nagpal0Austin G. Milton1Simon A. Koblar2M. Anne Hamilton-Bruce3Stroke Research Programme, Adelaide Medical School, University of AdelaideStroke Research Programme, The Queen Elizabeth HospitalStroke Research Programme, Adelaide Medical School, University of AdelaideStroke Research Programme, Adelaide Medical School, University of AdelaideAbstract Background Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigational cell therapies into viable medical products. Methods We developed a checklist using a mixed methodology approach to evaluate the impact of study design, regulatory policy, ethical, and health economic considerations for efficient implementation of early phase cell therapy studies. Results The checklist comprises a series of questions arranged under four domains: the first concerns study design such as characterization of target study population, trial design, endpoints and operational fit of dosage, time, and route of administration to target populations. A second domain addresses the data package required for regulatory approval relevant to the intended use (allogeneic/autologous; homologous/non-homologous; nature of cell processing). The third domain comprises patient involvement to ensure relevant data is collected via targeted study design. The final domain requires the team to determine the critical data elements that could be built into study design to enable health economic data collection to be started at an early phase of the study. Conclusions The CT2S checklist can help to determine areas of expertise gaps and enable research groups to appropriately allocate resources for capacity building. Use of this checklist will allow identification of key areas where trial planning needs to be optimized, as well as helping to identify resources that need to be secured. The CT2S checklist can also serve as a general cell therapy research decision aid to improve research output and accelerate new cell therapy development.https://doi.org/10.1186/s13287-021-02147-6Clinical translationCell therapies in strokeChecklistStudy designRegulatoryPatient and Public Involvement in Research (PPIR) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anjali Nagpal Austin G. Milton Simon A. Koblar M. Anne Hamilton-Bruce |
spellingShingle |
Anjali Nagpal Austin G. Milton Simon A. Koblar M. Anne Hamilton-Bruce Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products Stem Cell Research & Therapy Clinical translation Cell therapies in stroke Checklist Study design Regulatory Patient and Public Involvement in Research (PPIR) |
author_facet |
Anjali Nagpal Austin G. Milton Simon A. Koblar M. Anne Hamilton-Bruce |
author_sort |
Anjali Nagpal |
title |
Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_short |
Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_full |
Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_fullStr |
Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_full_unstemmed |
Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist—a pragmatic tool to accelerate development of cell therapy products |
title_sort |
clinical translation of cell therapies in stroke (ct2s) checklist—a pragmatic tool to accelerate development of cell therapy products |
publisher |
BMC |
series |
Stem Cell Research & Therapy |
issn |
1757-6512 |
publishDate |
2021-01-01 |
description |
Abstract Background Cell therapies present an exciting potential but there is a long history of expensive translational failures in stroke research. Researchers engaged in cell therapy research would benefit from a practical framework that can help in planning research and development of investigational cell therapies into viable medical products. Methods We developed a checklist using a mixed methodology approach to evaluate the impact of study design, regulatory policy, ethical, and health economic considerations for efficient implementation of early phase cell therapy studies. Results The checklist comprises a series of questions arranged under four domains: the first concerns study design such as characterization of target study population, trial design, endpoints and operational fit of dosage, time, and route of administration to target populations. A second domain addresses the data package required for regulatory approval relevant to the intended use (allogeneic/autologous; homologous/non-homologous; nature of cell processing). The third domain comprises patient involvement to ensure relevant data is collected via targeted study design. The final domain requires the team to determine the critical data elements that could be built into study design to enable health economic data collection to be started at an early phase of the study. Conclusions The CT2S checklist can help to determine areas of expertise gaps and enable research groups to appropriately allocate resources for capacity building. Use of this checklist will allow identification of key areas where trial planning needs to be optimized, as well as helping to identify resources that need to be secured. The CT2S checklist can also serve as a general cell therapy research decision aid to improve research output and accelerate new cell therapy development. |
topic |
Clinical translation Cell therapies in stroke Checklist Study design Regulatory Patient and Public Involvement in Research (PPIR) |
url |
https://doi.org/10.1186/s13287-021-02147-6 |
work_keys_str_mv |
AT anjalinagpal clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts AT austingmilton clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts AT simonakoblar clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts AT mannehamiltonbruce clinicaltranslationofcelltherapiesinstrokect2schecklistapragmatictooltoacceleratedevelopmentofcelltherapyproducts |
_version_ |
1724317355650056192 |